ICAP at Columbia University, New York, NY.
Division of Global HIV&TB, U.S. Centers for Disease Control and Prevention (CDC), Atlanta, GA.
J Acquir Immune Defic Syndr. 2021 Aug 1;87(Suppl 1):S81-S88. doi: 10.1097/QAI.0000000000002637.
HIV population viral load (PVL) can reflect antiretroviral therapy program effectiveness and transmission potential in a community. Using nationally representative data from household surveys conducted in Zimbabwe, Malawi, and Zambia in 2015-16, we examined the association between various VL measures and the probability of at least one recent HIV-1 infection in the community.
We used limiting-antigen avidity enzyme immunoassay, viral load suppression (VLS) (HIV RNA <1000 copies/mL), and antiretrovirals in the blood to identify recent HIV-1 cases.
Among 1510 enumeration areas (EAs) across the 3 surveys, 52,036 adults aged 15-59 years resided in 1363 (90.3%) EAs with at least one HIV-positive adult consenting to interview and blood draw and whose VL was tested. Mean HIV prevalence across these EAs was 13.1% [95% confidence intervals (CI) 12.7 to 13.5]. Mean VLS prevalence across these EAs was 58.7% (95% CI: 57.3 to 60.0). In multivariable analysis, PVL was associated with a recent HIV-1 case in that EA (adjusted odds ratio: 1.4, 95% CI: 1.2 to 1.6, P = 0.001). VLS prevalence was inversely correlated with recent infections (adjusted odds ratio: 0.3, 95% CI: 0.1 to 0.6, P = 0.004). The 90-90-90 indicators, namely, the prevalence of HIV diagnosis, antiretroviral therapy coverage, and VLS at the EA level, were inversely correlated with HIV recency at the EA level.
We found a strong association between PVL and VLS prevalence and recent HIV-1 infection at the EA level across 3 southern African countries with generalized HIV epidemics. These results suggest that population-based measures of VLS in communities may serve as a proxy for epidemic control.
HIV 人群病毒载量(PVL)可以反映社区中抗逆转录病毒治疗计划的效果和传播潜力。我们利用 2015-16 年在津巴布韦、马拉维和赞比亚进行的家庭调查的全国代表性数据,研究了各种 VL 测量指标与社区中至少有一次近期 HIV-1 感染的概率之间的关联。
我们使用限制抗原亲和力酶免疫测定、病毒载量抑制(VLS)(HIV RNA<1000 拷贝/ml)和血液中的抗逆转录病毒药物来识别近期 HIV-1 病例。
在这 3 项调查的 1510 个计数区(EA)中,有 52036 名年龄在 15-59 岁的成年人居住在 1363 个(90.3%)EA 中,这些 EA 中至少有一名同意接受访谈和采血且 VL 检测结果为阳性的成年人。这些 EA 中 HIV 的平均流行率为 13.1%[95%置信区间(CI)为 12.7-13.5]。这些 EA 中平均 VLS 流行率为 58.7%(95%CI:57.3-60.0)。在多变量分析中,PVL 与该 EA 中的近期 HIV-1 病例相关(调整后的优势比:1.4,95%CI:1.2-1.6,P=0.001)。VLS 流行率与近期感染呈负相关(调整后的优势比:0.3,95%CI:0.1-0.6,P=0.004)。在 EA 层面上,90-90-90 指标,即 HIV 诊断、抗逆转录病毒治疗覆盖率和 VLS 的流行率,与 EA 层面上 HIV 近期流行率呈负相关。
我们发现,在三个南部非洲国家,普遍存在 HIV 流行的情况下,PVL 与 VLS 流行率和 EA 层面上的近期 HIV-1 感染之间存在很强的关联。这些结果表明,社区中基于人群的 VLS 测量可能成为控制疫情的一个指标。